| 000 | 01631 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518031910.0 | ||
| 264 | 0 | _c20191127 | |
| 008 | 201911s 0 0 eng d | ||
| 022 | _a1097-6787 | ||
| 024 | 7 |
_a10.1016/j.jaad.2019.03.049 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPolansky, Maxim | |
| 245 | 0 | 0 |
_aRituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. _h[electronic resource] |
| 260 |
_bJournal of the American Academy of Dermatology _cJul 2019 |
||
| 300 |
_a179-186 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAcademic Medical Centers |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGeorgia |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPemphigoid, Bullous _xdiagnosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aRituximab _xadverse effects |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aEisenstadt, Rachel | |
| 700 | 1 | _aDeGrazia, Taryn | |
| 700 | 1 | _aZhao, Xiwen | |
| 700 | 1 | _aLiu, Yuan | |
| 700 | 1 | _aFeldman, Ron | |
| 773 | 0 |
_tJournal of the American Academy of Dermatology _gvol. 81 _gno. 1 _gp. 179-186 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jaad.2019.03.049 _zAvailable from publisher's website |
| 999 |
_c29527943 _d29527943 |
||